ReviewJournal of nephropathology2013
IgM nephropathy; can we still ignore it.
Review in Journal of nephropathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Comparison between characteristics of immunoglobulin M nephropathy and other glomerular diseases.Kidney research and clinical practice · 2025Article
- The outcome of rituximab in treating steroid dependent nephrotic syndrome.: Histopathology and immunosuppressive drugs as predicting factors.Saudi medical journal · 2022Article
- Pathological and Evolutive Correlations in Steroid Resistant Nephrotic Syndrome in Children.International journal of general medicine · 2022Article
- Article
- Renal Outcome of IgM Nephropathy: A Comparative Prospective Cohort Study.Journal of clinical medicine · 2021Article
- A case report of immunoglobulin M nephropathy manifesting as crescentic glomerulonephritis and nephrotic syndrome in an adult.BMC nephrology · 2019Article
- The impact of IgM deposits on the outcome of Nephrotic syndrome in children.BMC nephrology · 2017Article
- A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis.Kidney research and clinical practice · 2017Review
- IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?Journal of nephrology · 2016Review
- Article
- Pediatric Renal Biopsies in India: A Single-Centre Experience of Six Years.Nephro-urology monthly · 2015Article
- IgM nephropathy; time to act.Journal of nephropathology · 2014Article
- IgM nephropathy: timely response to a call for action.Journal of renal injury prevention · 2014Article
- Comment on: IgM nephropathy: Can we still ignore it.Journal of nephropathology · 2013Article
- Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: New concepts.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2013Article
- Association of proteinuria with various clinical findings and morphologic variables of oxford classification in immunoglobulin a nephropathy patients.International journal of preventive medicine · 2013Article
- Case Report: Acute Cerebellar Thrombosis in an Adult Patient with IgM Nephropathy.Methodist DeBakey cardiovascular journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextIgM nephropathy (IgMN) is a relatively less recognized clinico-immunopathological entity in the domain of glomerulonephritis , often thought to be a bridge between minimal change disease and focal segmental glomerulosclerosis. EVIDENCE ACQUISITIONS: Directory of Open Access Journals (DOAJ), Google Scholar, Pubmed (NLM), LISTA (EBSCO) and Web of Science has been searched.
resultsIgM nephropathy can present as nephritic syndrome or less commonly with subnephrotic proteinuria or rarely hematuria. About 30% patients respond to steroids whereas others are steroid dependent / resistant. They should be given a trial of Rituximab or stem cell therapy.
conclusionsIgM nephropathy (IgMN) is an important and rather neglected pathology responsible for renal morbidity in children and adults in developing countries as compared to developed nations with incidence of 2-18.5% of native biopsies. Abnormal T-cell function with hyperfunctioning suppressor T-cells are believed to be responsible for this disease entity. Approximately one third of the patients are steroid responders where as the remaining two thirds are steroid resistant or dependent. Therapeutic trials including cell therapies targeting suppressor T-cells are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.